Abstract | PURPOSE: METHODS: PDR patients were randomly assigned to treatment with either PRP + IVR or PIR + IVR. ETRDS Best-corrected visual acuity (BCVA) and central subfield thickness (CSFT) measured on optic-coherence tomography images (OCT-Heidelberg Spectralis) were recorded at baseline and every 4 weeks for one year. Fluorescein leakage area (FLA) from active new vessels was measured every 12 weeks. Full-field ERG was recorded by means of DTL electrodes, following ISCEV standard recommendations, at baseline and after 3 months. RESULTS: Twenty-eight eyes completed the study period. At baseline, mean ± SE BCVA (logMAR) was 0.44 ± 0.07 and 0.37 ± 0.08 (P = 0.5030); CSFT (μm) was 324.0 ± 20.4 and 330.1 ± 22.1 (P = 0.8417); and FLA (mm2) was 16.10 ± 4.42 and 9.97 ± 1.83 (P = 0.2114) for PRP + IVR and PIR + IVR groups, respectively. There were no relevant changes on BCVA or CSFT, but a significant reduction for FLA was observed at all visits compared to baseline for both groups, with no differences between groups. ERG showed at baseline reduced dark-adapted amplitudes, and these changes were also significantly amplified after laser treatment. ROD b-wave amplitude was further reduced in 62 ± 6% for PRP + IVR and 59 ± 4% for group PIR + IVR, but with no between-groups significant difference (P = 0.9082). CONCLUSIONS: PIR + IVR or PRP + IVR are comparable strategies regarding FLA control in PDR and led to similar retinal function impairment, based on ERG changes up to one-year follow-up. TRIAL REGISTRATION NUMBER: NCT03904056, date of registration 02/11/2019, retrospectively registered.
|
Authors | Luiza Toscano, Andre Messias, Katharina Messias, Rafaella de Cenço Lopes, Jefferson A Santana Ribeiro, Ingrid U Scott, Rodrigo Jorge |
Journal | Documenta ophthalmologica. Advances in ophthalmology
(Doc Ophthalmol)
Vol. 143
Issue 3
Pg. 313-322
(12 2021)
ISSN: 1573-2622 [Electronic] Netherlands |
PMID | 34347216
(Publication Type: Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Copyright | © 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature. |
Chemical References |
- Angiogenesis Inhibitors
- Ranibizumab
|
Topics |
- Angiogenesis Inhibitors
(therapeutic use)
- Diabetes Mellitus
(drug therapy)
- Diabetic Retinopathy
(drug therapy, surgery)
- Electroretinography
- Humans
- Intravitreal Injections
- Laser Coagulation
- Ranibizumab
(therapeutic use)
- Retina
(diagnostic imaging)
- Tomography, Optical Coherence
- Treatment Outcome
- Visual Acuity
|